Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease

JAMA Internal Medicine

Volumn 173, Issue 13, 2013, Pages 1222-1228

  Stender, Stefan ^a,b   Frikke Schmidt, Ruth ^a,b,c   Nordestgaard, Børge G ^b,c,d   Tybjræg Hansen, Anne ^a,b,c,d  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLELITHIASIS; CONTROLLED STUDY; DENMARK; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTIOXIDANTS; BILIRUBIN; BIOLOGICAL MARKERS; DENMARK; FEMALE; FOLLOW-UP STUDIES; GALLSTONES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84879996085     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.6465     Document Type: Article

References (34)

1. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-239. (Pubitemid 44037798)
2. Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol. 2012;36(2):122-129.
3. Dutt MK, Murphy GM, Thompson RP. Unconjugated bilirubin in human bile: the nucleating factor in cholesterol cholelithiasis? J Clin Pathol. 2003;56(8):596-598. (Pubitemid 36976357)
4. Duvaldestin P, Mahu JL,Metreau JM, Arondel J, Preaux AM, Berthelot P. Possible role of a defect in hepatic bilirubin glucuronidation in the initiation of cholesterol gallstones. Gut. 1980;21(8):650-655. (Pubitemid 10020936)
5. Ostrow JD. Unconjugated bilirubin and cholesterol gallstone formation. Hepatology. 1990;12(3 pt 2):219S-226S. (Pubitemid 20353277)
6. Wang DQ, Carey MC. Characterization of crystallization pathways during cholesterol precipitation from human gallbladder biles: identical pathways to corresponding model biles with three predominating sequences. J Lipid Res. 1996;37(12):2539-2549. (Pubitemid 27051501)
7. Gallinger S, Harvey PR, Petrunka CN, Strasberg SM. Effect of binding of ionised calcium on the in vitro nucleation of cholesterol and calcium bilirubinate in human gall bladder bile. Gut. 1986;27(11):1382-1386. (Pubitemid 17175690)
8. Portincasa P,Wang DQ. Intestinal absorption, hepatic synthesis, and biliary secretion of cholesterol: where are we for cholesterol gallstone formation? Hepatology. 2012;55(5):1313-1316.
9. Buch S, Schafmayer C, Völzke H, et al. Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology. 2010;139(6):1942-1951; e2.
10. Kitsiou-Tzeli S, Kanavakis E, Tzetis M, Kavazarakis E, Galla A, Tsezou A. Gilbert's syndrome as a predisposing factor for idiopathic cholelithiasis in children. Haematologica. 2003;88(10):1193-1194. (Pubitemid 37362555)
11. Tsezou A, Tzetis M, Giannatou E, et al. Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population. Genet Test Mol Biomarkers. 2009;13(1):143-146.
12. Stender S, Frikke-Schmidt R, Benn M, Nordestgaard BG, Tybjærg-Hansen A. Low-density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses. J Hepatol. 2013;58(1):126-133.
13. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133-1163. (Pubitemid 351395448)
14. Nordestgaard BG, Tybjærg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol. 2011;22(2):113-122.
15. Bowden J, Vansteelandt S. Mendelian randomization analysis of case-control data using structural mean models. Stat Med. 2011;30(6):678-694.
16. Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Sterol transporter adenosine triphosphate-binding cassette transporter G8, gallstones, and biliary cancer in 62,000 individuals from the general population. Hepatology. 2011;53(2):640-648.
17. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908.
18. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142-2152.
19. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk ofmyocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184.
20. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk ofmyocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308. (Pubitemid 47080484)
21. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med. 2013;273(1):59-68.
22. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333(18):1171-1175.
23. Wasmuth HE, Keppeler H, Herrmann U, Schirin-Sokhan R, BarkerM, Lammert F. Coinheritance of Gilbert syndrome-associated UGT1A1 mutation increases gallstone risk in cystic fibrosis. Hepatology. 2006;43(4):738-741.
24. Borgna-Pignatti C, Rigon F, Merlo L, et al. Thalassemiaminor, the Gilbert mutation, and the risk of gallstones. Haematologica. 2003;88(10):1106-1109. (Pubitemid 37362541)
25. Chaar V, Kéclard L, Diara JP, et al. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia. Haematologica. 2005;90(2):188-199.
26. del Giudice EM, Perrotta S, Nobili B, Specchia C, d'Urzo G, Iolascon A. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood. 1999;94(7):2259-2262.
27. Economou M, Tsatra I, Athanassiou-Metaxa M. Simultaneous presence of Gilbert syndrome and hereditary spherocytosis: interaction in the pathogenesis of hyperbilirubinemia and gallstone formation. Pediatr Hematol Oncol. 2003;20(6):493-495. (Pubitemid 37039940)
28. Galanello R, Piras S, Barella S, et al. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia. Br J Haematol. 2001;115(4):926-928. (Pubitemid 34042911)
29. Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood. 2005;105(3):968-972. (Pubitemid 40170862)
30. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A. 1997;94(22):12128-12132. (Pubitemid 27467854)
31. Passon RG, Howard TA, Zimmerman SA, Schultz WH,Ware RE. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol. 2001;23(7):448-451. (Pubitemid 33031774)
32. Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet. 2001;357(9272):1945-1946. (Pubitemid 32568338)
33. Johnson AD, Kavousi M, Smith AV, et al. Genome-wide associationmeta- analysis for total serum bilirubin levels. Hum Mol Genet. 2009;18(14):2700-2710.
34. Strassburg CP. Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? Drug Metab Rev. 2010;42(1):168-181.